SEC Form SC 13G/A filed by Silverback Therapeutics Inc. (Amendment)

2/14/23 4:35:55 PM ET

Specialty Chemicals

Consumer Discretionary

Get the next $SBTX alert in real time by email

SC 13G/A 1 tm236482d1_sc13ga.htm SC 13G/A


	UNITED STATES
	SECURITIES AND EXCHANGE COMMISSION
	Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

ARS Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

82835W 10 8

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨	Rule 13d-1(b)

¨	Rule 13d-1(c)

x	Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 82835W 10 8

	1.	Names of Reporting Persons Nextech VI Oncology SCSp

	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		¨
		(b)		x (1)

	3.	SEC Use Only

	4.	Citizenship or Place of Organization Luxembourg

Number of Shares Beneficially Owned by Each Reporting Person With			5.		Sole Voting Power 1,910,029 shares

			6.		Shared Voting Power 0

			7.		Sole Dispositive Power 1,910,029 shares

			8.		Shared Dispositive Power 0

	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,910,029 shares

	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

	11.	Percent of Class Represented by Amount in Row (9) 2.0% (2)

	12.	Type of Reporting Person (See Instructions) PN

(1)

This Schedule 13G is filed by Nextech VI Oncology SCSp (“Nextech VI LP”), Nextech VI GP S.à. r.l. (“Nextech VI GP”), Rocco Sgobbo (“Sgobbo”), Dalia Bleyer (“Bleyer”) and Ian Charoub (“Charoub” and together with Nextech VI LP, Nextech VI GP, Sgobbo and Bleyer, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

The percent of class was calculated based on 93,770,165 shares of Common Stock outstanding as of November 8, 2022, as reported in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 8, 2022.

CUSIP No. 82835W 10 8

	1.	Names of Reporting Persons Nextech VI GP S.à r.l.

	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		¨
		(b)		x (1)

	3.	SEC Use Only

	4.	Citizenship or Place of Organization Luxembourg

Number of Shares Beneficially Owned by Each Reporting Person With			5.		Sole Voting Power 1,910,029 shares

			6.		Shared Voting Power 0

			7.		Sole Dispositive Power 1,910,029 shares

			8.		Shared Dispositive Power 0

	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,910,029 shares

	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

	11.	Percent of Class Represented by Amount in Row (9) 2.0% (2)

	12.	Type of Reporting Person (See Instructions) OO

(1)

This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

CUSIP No. 82835W 10 8

	1.	Names of Reporting Persons Rocco Sgobbo

	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		¨
		(b)		x (1)

	3.	SEC Use Only

	4.	Citizenship or Place of Organization Switzerland

Number of Shares Beneficially Owned by Each Reporting Person With			5.		Sole Voting Power 0

			6.		Shared Voting Power 1,910,029 shares

			7.		Sole Dispositive Power 0

			8.		Shared Dispositive Power 1,910,029 shares

	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,910,029 shares

	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

	11.	Percent of Class Represented by Amount in Row (9) 2.0% (2)

	12.	Type of Reporting Person (See Instructions) IN

(1)

This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

CUSIP No. 82835W 10 8

	1.	Names of Reporting Persons Dalia Bleyer

	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		¨
		(b)		x (1)

	3.	SEC Use Only

	4.	Citizenship or Place of Organization Lithuania

Number of Shares Beneficially Owned by Each Reporting Person With			5.		Sole Voting Power 0

			6.		Shared Voting Power 1,910,029 shares

			7.		Sole Dispositive Power 0

			8.		Shared Dispositive Power 1,910,029 shares

	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,910,029 shares

	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

	11.	Percent of Class Represented by Amount in Row (9) 2.0% (2)

	12.	Type of Reporting Person (See Instructions) IN

(1)

This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

CUSIP No. 82835W 10 8

	1.	Names of Reporting Persons Ian Charoub

	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)		¨
		(b)		x (1)

	3.	SEC Use Only

	4.	Citizenship or Place of Organization Sweden

Number of Shares Beneficially Owned by Each Reporting Person With			5.		Sole Voting Power 0

			6.		Shared Voting Power 1,910,029 shares

			7.		Sole Dispositive Power 0

			8.		Shared Dispositive Power 1,910,029 shares

	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 1,910,029 shares

	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

	11.	Percent of Class Represented by Amount in Row (9) 2.0% (2)

	12.	Type of Reporting Person (See Instructions) IN

(1)

This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

(2)

Introductory Note: This statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock (“Common Stock”) of ARS Pharmaceuticals, Inc. f/k/a Silverback Therapeutics, Inc.(the “Issuer”).

Item 1.

	(a)	Name of Issuer: ARS Pharmaceuticals, Inc.
	(b)	Address of Issuer’s Principal Executive Offices: 11682 El Camino Real, Suite 120 San Diego, California 92130

Item 2.

	(a)	Name of Reporting Persons Filing: Nextech VI Oncology SCSp (“Nextech VI LP”) Nextech VI GP S.à r.l. (“Nextech VI GP”) Rocco Sgobbo (“Sgobbo”) Dalia Bleyer (“Bleyer”) Ian Charoub (“Charoub”)
	(b)	Address of Principal Business Office or, if none, Residence: 8 rue Lou Hemmer L-1748 Luxembourg-Findel Grand-Duché de Luxembourg
	(c)	Citizenship
		Name	Citizenship or Place of Organization
		Nextech VI LP	Luxembourg
		Nextech VI GP	Luxembourg

		Sgobbo	Switzerland
		Bleyer	Lithuania
		Charoub	Sweden
	(d)	Title of Class of Securities: Common Stock, par value $0.0001 per share
	(e)	CUSIP Number: 82835W 10 8

Item 3.	If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

	Not applicable

Item 4.

Ownership

The following information with respect to the ownership of Common Stock of the Issuer by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2022.

Reporting Persons	Shares of Common Stock Held Directly		Sole Voting Power		Shared Voting Power (1)		Sole Dispositive Power		Shared Dispositive Power (1)		Beneficial Ownership		Percentage of Class (1) (2)
Nextech VI LP		1,910,029		1,910,029		0		1,910,029		0		1,910,029		2.0	%
Nextech VI GP (1)		0		1,910,029		0		1,910,029		0		1,910,029		2.0	%
Sgobbo (1)		0		0		1,910,029		0		1,910,029		1,910,029		2.0	%
Bleyer (1)		0		0		1,910,029		0		1,910,029		1,910,029		2.0	%
Charoub (1)		0		0		1,910,029		0		1,910,029		1,910,029		2.0	%

(1)

The shares are held by Nextech VI LP. Nextech VI GP serves as the sole general partner of Nextech VI LP and has sole voting and investment control over the shares owned by Nextech VI LP and may be deemed to own beneficially the shares held by Nextech VI LP. Nextech VI GP owns no securities of the Issuer directly. Sgobbo, Bleyer and Charoub are members of the board of managers of Nextech VI GP and share voting and dispositive power over the shares held by Nextech VI LP, and may be deemed to own beneficially the shares held by Nextech VI LP. The managing members own no securities of the Issuer directly.

(2)

Item 5.	Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

Item 6.	Ownership of More than Five Percent on Behalf of Another Person

Not applicable

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable

Item 8.	Identification and Classification of Members of the Group

Not applicable

Item 9.	Notice of Dissolution of Group

Not applicable

Item 10.	Certification

Not applicable

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2023

Nextech VI Oncology SCSp

By:	Nextech VI GP S.à r.l.
its	General Partner

By:	/s/ Dalia Bleyer
	Dalia Bleyer, Managing Member

By:	/s/ Rocco Sgobbo
	Rocco Sgobbo, Managing Member

Nextech VI GP S.à r.l.

By:	/s/ Dalia Bleyer
	Dalia Bleyer, Managing Member

By:	/s/ Rocco Sgobbo
	Rocco Sgobbo, Managing Member

/s/ Rocco Sgobbo
Rocco Sgobbo

/s/ Dalia Bleyer
Dalia Bleyer

/s/ Ian Charoub
Ian Charoub

Get the next $SBTX alert in real time by email

Date	Price Target	Rating	Analyst
4/4/2022	$25.00 → $3.50	Buy → Neutral	Goldman
4/1/2022	$25.00 → $1.80	Outperform → Mkt Perform	SVB Leerink
4/1/2022	$32.00 → $6.00	Buy → Hold	Stifel
4/1/2022		Buy → Neutral	H.C. Wainwright
11/12/2021	$42.00 → $25.00	Outperform	SVB Leerink
8/16/2021	$46.00 → $49.00	Outperform	SVB Leerink

SEC Form SC 13G/A filed by Silverback Therapeutics Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for
$SBTX

$SBTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Lowenthal Richard E gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 20% to 4,126,822 units (SEC Form 4)

SEC Form 4 filed by Karas Eric

Tanimoto Sarina gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 24% to 3,276,854 units (SEC Form 4)

$SBTX
Press Releases

Fastest customizable press release news feed in the world

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

Silverback Therapeutics, Inc. announces the FDA's acceptance of ARS Pharmaceuticals' NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

$SBTX
Leadership Updates

Live Leadership Updates

Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors

$SBTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.